American Diabetes Association (ADA) 78th Scientific Sessions
American Diabetes Association (ADA) 78th Scientific Sessions
Upon successful registration, you will be able to download an ADA Certificate of Participation
Login button
Upon successful registration, you will be able
to download an ADA Certificate of Participation
Webcasts
Saturday, June 10th
Efficacy and Safety of Liraglutide in Insulin-Pump-Treated People with Type 1 Diabetes: The Lira Pump Trial
Thomas F. Dejgaard, MD - Steno Diabetes Center Copenhagen
 
Twenty-Four-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes (inTandem1)
John B. Buse, MD, PhD - University of North Carolina School of Medicine
 
A Decrease In Insulin Action, But Not In ß-Cell Function, Impairs Glucagon Suppression In Nondiabetic Humans
Ron T. Varghese MBBS - Mayo Clinic
 
Metabolism, In Vivo (Animals) Beta-Cell Sensitivity To Incretin Infusions In Healthy Adults
Mark D. Miller MD - Duke University Medical System
 
Friday, June 9th
CGM Outcomes―How Current Recommendations Regarding Time in Range, Hypoglycemia, Hyperglycemia, Glucose Variability, and Glucose Pattern Visualization Agree and Differ
Richard Bergenstal, MD - International Diabetes Center
 
Key Issues in Adopting and Implementing Standardized CGM Outcome Metrics
Simon R. Heller, FRCP, DM - University Of Sheffield
 
Sunday, June 11th
SGLT2 Inhibitors2
David Cherney, MD, CM, PhD, FRCP(C) - University Of Toronto
 
GLP-1 Receptor Agonists
Katherine R. Tuttle, MD, FACP, FASN, FNKF - University Of Washington School Of Medicine
 
DPP-4 Inhibitors
Mark Emmanuel Cooper, MBBS, PhD - Monash University
 
Monday, June 12th
Nasal Glucagon for the Treatment of Moderate-to-Severe Hypoglycemic Episodes in Real-World Settings in Adults with Type 1 Diabetes
Elizabeth R. Seaquist, MD University of Minnesota